Provided by Tiger Fintech (Singapore) Pte. Ltd.

Editas Medicine

1.47
-0.0900-5.77%
Volume:2.97M
Turnover:4.25M
Market Cap:121.98M
PE:-0.51
High:1.58
Open:1.57
Low:1.36
Close:1.56
Loading ...

Chardan Cuts Price Target on Editas Medicine to $12 From $20, Keeps Buy Rating

MT Newswires Live
·
23 Oct 2024

Editas Medicine price target lowered to $12 from $20 at Chardan

TIPRANKS
·
23 Oct 2024

Editas Medicine Is Maintained at Buy by Chardan Capital

Dow Jones
·
23 Oct 2024

Promising Financial Position and Advancements Propel Editas Medicine to a ‘Buy’ Rating

TIPRANKS
·
23 Oct 2024

Possible Signal As Editas Medicine Insiders Sell US$1.2m In Stock

Simply Wall St.
·
23 Oct 2024

Buy Rating for Editas Medicine: Promising In Vivo CRISPR Platform and Strategic Growth Potential Amid Speculative Investment

TIPRANKS
·
23 Oct 2024

Editas Medicine price target lowered to $10 from $18 at Baird

TIPRANKS
·
23 Oct 2024

EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies

Zacks
·
22 Oct 2024

Editas Medicine Achieves Proof of Concept for In Vivo Gene Editing of Hematopoietic Stem Cells in Humanized Mice

MT Newswires Live
·
22 Oct 2024

Editas reviews path for gene editing therapy to save costs

seekingalpha
·
22 Oct 2024

Editas Medicine announces progress towards 2024 goals

TIPRANKS
·
22 Oct 2024

Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of in Vivo Preclinical Proof of Concept and Strategic Update

THOMSON REUTERS
·
22 Oct 2024

Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update

GlobeNewswire
·
22 Oct 2024

Editas Medicine, Genevant Partner to Develop mRNA-LNP Gene Editing Therapeutics

MT Newswires Live
·
22 Oct 2024

BRIEF-Editas Medicine And Genevant Sciences To Collaborate To Develop Novel Mrna-Lnp Gene Editing Therapeutics

Reuters
·
22 Oct 2024

Editas Medicine, Genevant Sciences enter collaboration and license agreement

TIPRANKS
·
22 Oct 2024